103 related articles for article (PubMed ID: 11796150)
1. A study of the nicotinic agonist SIB-1553A on locomotion and attention as measured by the five-choice serial reaction time task.
Grottick AJ; Wyler R; Higgins GA
Pharmacol Biochem Behav; 2001 Dec; 70(4):505-13. PubMed ID: 11796150
[TBL] [Abstract][Full Text] [Related]
2. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors.
Bontempi B; Whelan KT; Risbrough VB; Lloyd GK; Menzaghi F
Neuropsychopharmacology; 2003 Jul; 28(7):1235-46. PubMed ID: 12700710
[TBL] [Abstract][Full Text] [Related]
3. In vitro pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a nicotinic acetylcholine receptor ligand.
Rao TS; Adams PB; Correa LD; Santori EM; Sacaan AI; Reid RT; Suto CM; Vernier JM
Brain Res; 2003 Aug; 981(1-2):85-98. PubMed ID: 12885429
[TBL] [Abstract][Full Text] [Related]
4. Effects of (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys.
Terry AV; Risbrough VB; Buccafusco JJ; Menzaghi F
J Pharmacol Exp Ther; 2002 Apr; 301(1):284-92. PubMed ID: 11907185
[TBL] [Abstract][Full Text] [Related]
5. SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates.
Bontempi B; Whelan KT; Risbrough VB; Rao TS; Buccafusco JJ; Lloyd GK; Menzaghi F
J Pharmacol Exp Ther; 2001 Oct; 299(1):297-306. PubMed ID: 11561092
[TBL] [Abstract][Full Text] [Related]
6. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Schneider JS; Tinker JP; Menzaghi F; Lloyd GK
J Pharmacol Exp Ther; 2003 Jul; 306(1):401-6. PubMed ID: 12721323
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thiophenol hydrochloride (SIB-1553A), a novel cholinergic ligand: microdialysis studies.
Rao TS; Reid RT; Correa LD; Santori EM; Gardner MF; Sacaan AI; Lorrain D; Vernier JM
Brain Res; 2003 Oct; 986(1-2):71-81. PubMed ID: 12965231
[TBL] [Abstract][Full Text] [Related]
8. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task.
Grottick AJ; Higgins GA
Behav Brain Res; 2000 Dec; 117(1-2):197-208. PubMed ID: 11099773
[TBL] [Abstract][Full Text] [Related]
9. Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys.
Decamp E; Schneider JS
Eur J Neurosci; 2006 Oct; 24(7):2098-104. PubMed ID: 17067307
[TBL] [Abstract][Full Text] [Related]
10. Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands.
Grottick AJ; Haman M; Wyler R; Higgins GA
Neuropsychopharmacology; 2003 May; 28(5):880-7. PubMed ID: 12637951
[TBL] [Abstract][Full Text] [Related]
11. Strain dependency of the effects of nicotine and mecamylamine in a rat model of attention.
Hahn B; Riegger KE; Elmer GI
Psychopharmacology (Berl); 2016 Apr; 233(8):1427-34. PubMed ID: 26875755
[TBL] [Abstract][Full Text] [Related]
12. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats.
Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
J Pharmacol Exp Ther; 1997 Jan; 280(1):384-92. PubMed ID: 8996219
[TBL] [Abstract][Full Text] [Related]
13. Effects of nicotine and mecamylamine on choice accuracy in an operant visual signal detection task in female rats.
Rezvani AH; Bushnell PJ; Levin ED
Psychopharmacology (Berl); 2002 Dec; 164(4):369-75. PubMed ID: 12457266
[TBL] [Abstract][Full Text] [Related]
14. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.
Decamp E; Schneider JS
Brain Res; 2009 Mar; 1262():109-14. PubMed ID: 19368843
[TBL] [Abstract][Full Text] [Related]
15. Modulation of nicotine-induced attentional enhancement in rats by adrenoceptor antagonists.
Hahn B; Stolerman IP
Psychopharmacology (Berl); 2005 Feb; 177(4):438-47. PubMed ID: 15252705
[TBL] [Abstract][Full Text] [Related]
16. Nicotine in an animal model of attention.
Stolerman IP; Mirza NR; Hahn B; Shoaib M
Eur J Pharmacol; 2000 Mar; 393(1-3):147-54. PubMed ID: 10771008
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of SIB-1663, a conformationally rigid analog of nicotine.
Rao TS; Sacaan AI; Menzaghi FM; Reid RT; Adams PB; Correa LD; Whelan KT; Vernier JM
Brain Res; 2004 Apr; 1003(1-2):42-53. PubMed ID: 15019562
[TBL] [Abstract][Full Text] [Related]
18. 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors.
Vernier JM; El-Abdellaoui H; Holsenback H; Cosford ND; Bleicher L; Barker G; Bontempi B; Chavez-Noriega L; Menzaghi F; Rao TS; Reid R; Sacaan AI; Suto C; Washburn M; Lloyd GK; McDonald IA
J Med Chem; 1999 May; 42(10):1684-6. PubMed ID: 10346920
[No Abstract] [Full Text] [Related]
19. Different effects of ionotropic and metabotropic glutamate receptor antagonists on attention and the attentional properties of nicotine.
Quarta D; Naylor CG; Morris HV; Patel S; Genn RF; Stolerman IP
Neuropharmacology; 2007 Sep; 53(3):421-30. PubMed ID: 17631918
[TBL] [Abstract][Full Text] [Related]
20. Radiosynthesis and ex vivo evaluation of [11C]-SIB-1553A as a PET radiotracer for beta4 selective subtype nicotinic acetylcholine receptor.
Sobrio F; Quentin T; Dhilly M; Bourdier T; Tymciu S; Debruyne D; Barré L
Nucl Med Biol; 2008 Apr; 35(3):377-85. PubMed ID: 18355694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
